24484-98-8

Basic information

• Product Name: 2,3-Diamino-4-chloropyridine
• Synonyms: 2,3-Diamino-4-chloropyridine;2,3-Diamino-4-chloropyrid...;4-chloro-2,3-diaMinopyridine;2,3-PyridinediaMine, 4-chloro-
• CAS NO: 24484-98-8
• Molecular Formula: C₅H₆ClN₃
• Molecular Weight: 143.576
• EINECS: 201-525-2
• Mol File: 24484-98-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 314oC at 760 mmHg
• Flash Point: 143.7oC
• Appearance: /
• Density: 1.447g/cm3
• Vapor Pressure: 0.00048mmHg at 25°C
• Refractive Index: 1.685
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• Solubility: Chloroform (Slightly, Sonicated), DMSO (Slightly), Ethyl Acetate (Slightly, Soni
• PKA: 5.68±0.47(Predicted)
• CAS DataBase Reference: 2,3-Diamino-4-chloropyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Diamino-4-chloropyridine(24484-98-8)
• EPA Substance Registry System: 2,3-Diamino-4-chloropyridine(24484-98-8)

Safety Data

• RIDADR: UN2671
• Hazardous Substances Data: 24484-98-8(Hazardous Substances Data)

Usage

General Description

2,3-Diamino-4-chloropyridine is a chemical compound with the molecular formula C5H6ClN3. It is a heterocyclic aromatic compound that contains a pyridine ring and two amino groups. 2,3-Diamino-4-chloropyridine is used in the synthesis of pharmaceuticals and agrochemicals. It is also used as a building block in the production of various organic compounds. The compound is known for its potential applications in medicinal chemistry and as an intermediate in the manufacturing of active pharmaceutical ingredients. However, it is important to handle this compound with care, as it may pose risks to human health and the environment if not properly managed.

InChI:InChI=1/C5H6ClN3/c6-3-1-2-9-5(8)4(3)7/h1-2H,7H2,(H2,8,9)

Upstream product

• 6980-08-1 4-chloro-3-nitro-2-pyridinamine 
• 19798-80-2 2-Amino-4-chloropyridine 

Downstream Products

• 6980-11-6 7-chloro-3H-imidazo<4,5-b>pyridine 
• 1533399-01-7 N-(3-(7-chloro-3H-imidazo[4,5-b]pyridin-2-yl)-4-fluorophenyl)furan-2-carboxamide 
• 1392428-92-0 8-chloropyrido[2,3-b]pyrazine 
• 1086423-62-2 7-chloro-2-methyl-3H-imidazo[4,5-b]pyridine 
• 26271-15-8 7-Chlor-1,2,5-selenadiazolo<3,4-b>pyridin 
• 1086423-42-8 7-chloro-3-(methoxymethyl)-2-methyl-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)-3H-imidazo[4,5-b]pyridine-6-carboxamide 

Relevant articles and documents

Identification of 2,4-Disubstituted Imidazopyridines as Hemozoin Formation Inhibitors with Fast-Killing Kinetics and in Vivo Efficacy in the Plasmodium falciparum NSG Mouse Model

A series of 2,4-disubstituted imidazopyridines, originating from a SoftFocus Kinase library, was identified from a high throughput phenotypic screen against the human malaria parasite Plasmodium falciparum. Hit compounds showed moderate asexual blood stage activity. During lead optimization, several issues were flagged such as cross-resistance against the multidrug-resistant K1 strain, in vitro cytotoxicity, and cardiotoxicity and were addressed through structure-Activity and structure-property relationship studies. Pharmacokinetic properties were assessed in mice for compounds showing desirable in vitro activity, a selectivity window over cytotoxicity, and microsomal metabolic stability. Frontrunner compound 37 showed good exposure in mice combined with good in vitro activity against the malaria parasite, which translated into in vivo efficacy in the P. falciparum NOD-scid IL-2Rnull (NSG) mouse model. Preliminary mechanistic studies suggest inhibition of hemozoin formation as a contributing mode of action.

Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors

A series of pyrrolo[2,3-b]pyridine-based derivatives were designed as potent Bruton's tyrosine kinase (BTK) inhibitors by using a scaffold-hopping strategy. Structure-activity relationship studies identified five compounds (3n, 3p, 3q, 3r, and 3s) with IC

PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF

The invention provides compounds of formula (l) and pharmaceutical compositions thereof, which are useful as protein kinase inhibitors, and methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated kinase activity. In some embodiments, the invention provides methods for using such compounds to treat, ameliorate or prevent diseases or disorders that involve abnormal activation of AIk, AbI, Aurora-A, B-Raf, C-Raf, Bcr-Abl, BRK, BIk, Bmx, BTK, c-Kit, c-RAF, CSK, c-SRC, EphBl, EphB2, EphB4, FLTl, Fms, Flt3, Fyn, FRK3, JAK2, KDR, Lck, Lyn, PDGFRalpha, PDGFRbeta, PKCalpha, SAPK2alpha, Src, SIK, Syk, Tie2 and TrkB kinases.